Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79580.020.1194%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Regeneron Pharmaceuticals Inc

REGNNASDAQ
Trade with Public
Trade with Public
$827.72
-15.75-1.87%
At close: Sep 4, 5:00 PM EST
$827.72
N/A
After Hours: 4:15 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipDividendsCompareOptionsStock Report

Regeneron Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Regeneron Pharmaceuticals (REGN).

Price Target Range — 6 Quarters

Analyst Consensus — 23 Analysts

17Buy
6Hold
Consensus RatingBuy# Analysts23Avg. Consensus PT$797Upside to Avg. PT-3.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 17, 2026Leerink PartnersDavid RisingerPT RaiseMarket Perform$641→$824
Aug 3, 2026CitigroupGeoff MeachamPT RaiseNeutral$700→$740
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citigroup Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $740

Citigroup analyst Geoff Meacham maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and raises the price target from $700 to $740.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1030

Guggenheim analyst Brad Canino maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $1000 to $1030.
Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $737

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $696 to $737.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $758

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $730 to $758.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $795

Cantor Fitzgerald analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $750 to $795.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $750

Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $700 to $750.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved